Free Trial
NASDAQ:DNTH

Dianthus Therapeutics (DNTH) Stock Price, News & Analysis

Dianthus Therapeutics logo
$35.65 -0.35 (-0.97%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$35.66 +0.01 (+0.01%)
As of 10/17/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Dianthus Therapeutics Stock (NASDAQ:DNTH)

Advanced

Key Stats

Today's Range
$34.63
$36.33
50-Day Range
$18.89
$39.55
52-Week Range
$13.36
$40.16
Volume
657,913 shs
Average Volume
672,953 shs
Market Capitalization
$1.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.88
Consensus Rating
Moderate Buy

Company Overview

Dianthus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

DNTH MarketRank™: 

Dianthus Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 505th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dianthus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 10 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Dianthus Therapeutics has a consensus price target of $60.88, representing about 70.8% upside from its current price of $35.65.

  • Amount of Analyst Coverage

    Dianthus Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Dianthus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dianthus Therapeutics is -10.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dianthus Therapeutics is -10.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Dianthus Therapeutics has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Dianthus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    17.08% of the float of Dianthus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dianthus Therapeutics has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Dianthus Therapeutics has recently decreased by 3.12%, indicating that investor sentiment is improving.
  • Dividend Yield

    Dianthus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Dianthus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.08% of the float of Dianthus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Dianthus Therapeutics has a short interest ratio ("days to cover") of 7.8.
  • Change versus previous month

    Short interest in Dianthus Therapeutics has recently decreased by 3.12%, indicating that investor sentiment is improving.
  • News Sentiment

    Dianthus Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Dianthus Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 8 people have searched for DNTH on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $700,000.00 in company stock.

  • Percentage Held by Insiders

    Only 8.15% of the stock of Dianthus Therapeutics is held by insiders.

  • Percentage Held by Institutions

    47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Dianthus Therapeutics' insider trading history.
Receive DNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DNTH Stock News Headlines

Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
See More Headlines

DNTH Stock Analysis - Frequently Asked Questions

Dianthus Therapeutics' stock was trading at $21.80 at the start of the year. Since then, DNTH stock has increased by 63.5% and is now trading at $35.65.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) issued its quarterly earnings data on Thursday, August, 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.86) by $0.02. The business had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative trailing twelve-month return on equity of 34.72% and a negative net margin of 2,364.56%.

Dianthus Therapeutics' top institutional investors include Ethic Inc. (0.02%). Insiders that own company stock include Fairmount Funds Management Llc, Simrat Randhawa and Ryan Savitz.
View institutional ownership trends
.

Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
8/07/2025
Today
10/19/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:DNTH
CIK
1690585
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$100.00
Low Price Target
$40.00
Potential Upside/Downside
+70.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.25)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$84.97 million
Net Margins
-2,364.56%
Pretax Margin
-2,364.60%
Return on Equity
-34.72%
Return on Assets
-32.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.12
Quick Ratio
13.12

Sales & Book Value

Annual Sales
$4.85 million
Price / Sales
236.40
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.91 per share
Price / Book
2.99

Miscellaneous

Outstanding Shares
32,188,000
Free Float
29,565,000
Market Cap
$1.15 billion
Optionable
Optionable
Beta
1.58
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:DNTH) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners